Every item on the wire - press releases, filings, ratings, everything. https://www.quantisnow.com/news/all-insights en-us Sun, 15 Nov 2026 06:18:05 GMT Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of The Boeing Company ("Boeing" or "the Company") (NYSE: BA) who received shares in connection with its December 2025 merger ("the Merger") with Spirit AeroSystems Holdings, Inc. ("Spirit") (NYSE:SPR) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Following the Merger with Spirit, shares of Boeing have declined significantly. If you are a shareholder who suffered a loss, cli https://www.quantisnow.com/insight/ba-investors-who-received-shares-of-the-boeing-company-in-6791843 https://www.quantisnow.com/insight/ba-investors-who-received-shares-of-the-boeing-company-in-6791843 Sun, 15 Nov 2026 04:06:00 GMT Learn how 60 Degrees Pharmaceuticals is building on its FDA-approved antimalarial ARAKODA® while advancing tafenoquine for a growing tick-borne disease with no FDA-approved treatmentManagement to discuss the hospitalized babesiosis study, upcoming interim data readout, potential regulatory pathway, U.S. market opportunity, and 2026 commercial expansion of ARAKODA® ORLANDO, FL / ACCESS Newswire / November 4, 2026 / RedChip Companies will host an investor webinar on Tuesday, November 10, 2026, at 4:15 p.m. ET with 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP).The exclusive event will feature Geoff Dow, Chairman and CEO, who will provide an overview of 60 Degrees Pharmaceuticals' strateg https://www.quantisnow.com/insight/join-60-degrees-pharmaceuticals-live-investor-webinar-advancing-tafenoquine-for-6791842 https://www.quantisnow.com/insight/join-60-degrees-pharmaceuticals-live-investor-webinar-advancing-tafenoquine-for-6791842 Wed, 04 Nov 2026 21:15:00 GMT A radically reimagined 1979 Chevrolet El Camino takes the top prize in the 2026 Hot Wheels Legends Tour Presented by Mobil 1 The fan-built car will be transformed into an official 1:64-scale Hot Wheels die-cast sold worldwide Tampa custom-car builder Matt McEntegart brings the global title back to the U.S. for the first time since 2022 Photos of the 2026 Hot Wheels Legends Tour winner and runners-up can be found HERE. Mattel, Inc. (NASDAQ:MAT), a leading global play and family entertainment company and owner of one of the world’s most iconic brand portfolios, today announced the 2026 winner of the Hot Wheels™ Legends Tour presented by Mobil 1, the world’s largest traveling car https://www.quantisnow.com/insight/hot-wheels-crowns-2026-legends-tour-winner-following-global-search-6791841 https://www.quantisnow.com/insight/hot-wheels-crowns-2026-legends-tour-winner-following-global-search-6791841 Sat, 14 Nov 2026 17:30:00 GMT Jane King hosts conversations on sovereign AI, fusion energy, global private credit and partner-led streaming infrastructure, airing at 6:30 p.m. ET across the United States, Latin America, MENA and Southeast Asia NEW YORK CITY, NY / ACCESS Newswire / November 14, 2026 / AI is driving record spending on data centers, and with it, soaring costs for storage, bandwidth and power. Fusion developers are racing to deliver clean, around-the-clock energy. International investors are looking for returns that don't move with the rest of their portfolios. And companies that already own the customer relationship want to own the screen, too.Tonight, New to The Street brings leaders working on each https://www.quantisnow.com/insight/new-to-the-street-show-780-premieres-tonight-on-bloomberg-6791840 https://www.quantisnow.com/insight/new-to-the-street-show-780-premieres-tonight-on-bloomberg-6791840 Sat, 14 Nov 2026 17:18:00 GMT Phase 2 results showed EloraTZP, an investigational combination of eloralintide and tirzepatide, delivered substantial weight loss and A1C improvements in participants with obesity and type 2 diabetesResults from TRIUMPH-1, TRIUMPH-2 and TRIUMPH-4 demonstrated retatrutide, an investigational triple agonist, reduced obstructive sleep apnea severity and knee osteoarthritis pain in adults with obesityPeople reported Foundayo was simple and easy to use in a new real-world evidence study, while patient-reported outcomes showed that participants treated with eloralintide reported reductions in food noise, food cravings and alcohol consumptionINDIANAPOLIS, Nov. 14, 2026 /PRNewswire/ -- Eli Lilly an https://www.quantisnow.com/insight/lilly-to-present-new-data-across-zepbound-foundayo-eloratzp-and-6791839 https://www.quantisnow.com/insight/lilly-to-present-new-data-across-zepbound-foundayo-eloratzp-and-6791839 Sat, 14 Nov 2026 17:01:00 GMT LUCIDITY met its prespecified primary endpoint; avexitide reduced the composite Level 2/3 hypoglycemic event rate by 55% compared to placebo (p=0.000003) Avexitide showed consistent, highly statistically significant reductions across all prespecified, multiplicity-controlled secondary event-rate endpoints vs. placebo Avexitide was generally well-tolerated with a favorable safety profile; adverse events during the double-blind treatment period were generally mild to moderate in severity Company to host an in-person and webcast investor KOL event tomorrow, November 15, at 11:45 AM ET Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") will present the res https://www.quantisnow.com/insight/amylyx-pharmaceuticals-presents-results-from-phase-3-lucidity-clinical-trial-6791838 https://www.quantisnow.com/insight/amylyx-pharmaceuticals-presents-results-from-phase-3-lucidity-clinical-trial-6791838 Sat, 14 Nov 2026 17:00:00 GMT LONG BEACH, Calif., Nov. 14, 2026 (GLOBE NEWSWIRE) -- Rocket Lab Corporation (NASDAQ:RKLB), a global leader in launch services and space systems, today announced mission success for its 100th Electron launch, setting a new record for reaching 100 launches faster than any other commercially developed rocket. "The Mountain God Rises" mission launched from Rocket Lab Launch Complex 1 in New Zealand at 6:30 p.m. on November 14, 2026, deploying the YAMATSUMI-II synthetic aperture radar (SAR) Earth-imaging satellite to a 575km low Earth orbit for the Institute for Q-shu Pioneers of Space, Inc. (iQPS). This mission marks Rocket Lab’s 11th Electron launch for iQPS with 100% mission success since https://www.quantisnow.com/insight/rocket-lab-hits-100-electron-launches-fastest-commercial-rocket-to-6791837 https://www.quantisnow.com/insight/rocket-lab-hits-100-electron-launches-fastest-commercial-rocket-to-6791837 Sat, 14 Nov 2026 07:02:55 GMT MIAMI, Nov. 13, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline on November 11th by Axe Compute (NASDAQ:AGPU), please note that the date of the conference call in the first paragraph was incorrect. It should have been November 17, 2026, instead of November 16, 2026. The corrected release follows: Axe Compute (NASDAQ:AGPU), a neocloud AI infrastructure company delivering dedicated, bare-metal GPU compute and large-scale AI factory build-outs at global scale, today announced it will hold a conference call and webcast to review financial results for the third quarter ended September 30, 2026, before market open on Tuesday, November 17, 2026. Speakers on the call will be https://www.quantisnow.com/insight/correction-axe-compute-to-host-q3-2026-financial-results-conference-6791836 https://www.quantisnow.com/insight/correction-axe-compute-to-host-q3-2026-financial-results-conference-6791836 Sat, 14 Nov 2026 04:05:00 GMT Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)), an innovation-driven, global biopharma company, today announced that five of its commercial medicines in China have been included in the country’s 2026 National Reimbursement Drug List (NRDL). The update includes two first-time listings, expanding patient access to treatments for gMG and schizophrenia, and three renewals, which maintain access across oncology and infectious disease. Zai Lab Products Newly Added or Renewed in 2026 NRDL: First-time listings: VYVGART Hytrulo® (efgartigimod alfa, subcutaneous injection): for the treatment of adult patients with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis ( https://www.quantisnow.com/insight/zai-lab-announces-first-time-inclusion-of-karxt-and-vyvgart-hytrulo-6791835 https://www.quantisnow.com/insight/zai-lab-announces-first-time-inclusion-of-karxt-and-vyvgart-hytrulo-6791835 Sat, 14 Nov 2026 03:26:00 GMT SCHEDULE 13G/A - Starling Oncology, Inc. (0001799191) (Subject) https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-starling-oncology-inc-6791834 https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-starling-oncology-inc-6791834 Sat, 14 Nov 2026 02:59:30 GMT 4 - NEXGEL, INC. (0001468929) (Issuer) https://www.quantisnow.com/insight/interim-ceo-kieser-brian-joseph-bought-732688-worth-of-shares-6791833 https://www.quantisnow.com/insight/interim-ceo-kieser-brian-joseph-bought-732688-worth-of-shares-6791833 Sat, 14 Nov 2026 02:59:13 GMT 4 - NEXGEL, INC. (0001468929) (Issuer) https://www.quantisnow.com/insight/director-glassman-steven-mark-bought-25003-worth-of-shares-4546-6791832 https://www.quantisnow.com/insight/director-glassman-steven-mark-bought-25003-worth-of-shares-4546-6791832 Sat, 14 Nov 2026 02:58:28 GMT SCHEDULE 13G/A - EXAGEN INC. (0001274737) (Subject) https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-exagen-inc-6791831 https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-exagen-inc-6791831 Sat, 14 Nov 2026 02:58:28 GMT 4 - NEXGEL, INC. (0001468929) (Issuer) https://www.quantisnow.com/insight/chief-financial-officer-blackman-ian-howard-was-granted-4546-units-6791830 https://www.quantisnow.com/insight/chief-financial-officer-blackman-ian-howard-was-granted-4546-units-6791830 Sat, 14 Nov 2026 02:58:30 GMT 4 - NEXGEL, INC. (0001468929) (Issuer) https://www.quantisnow.com/insight/director-ciardiello-steven-was-granted-4546-units-of-convertible-promissory-6791829 https://www.quantisnow.com/insight/director-ciardiello-steven-was-granted-4546-units-of-convertible-promissory-6791829 Sat, 14 Nov 2026 02:58:32 GMT SCHEDULE 13G - Haymaker Acquisition Corp V (0002111838) (Subject) https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-haymaker-acquisition-corp-v-6791828 https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-haymaker-acquisition-corp-v-6791828 Sat, 14 Nov 2026 02:51:12 GMT SCHEDULE 13D/A - THOMSON REUTERS CORP /CAN/ (0001075124) (Subject) https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-thomson-reuters-corporation-6791827 https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-thomson-reuters-corporation-6791827 Sat, 14 Nov 2026 02:46:52 GMT SCHEDULE 13G/A - DEEP FISSION, INC. (0001918102) (Subject) https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-deep-fission-inc-6791826 https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-deep-fission-inc-6791826 Sat, 14 Nov 2026 02:45:22 GMT 4 - Neuronetics, Inc. (0001227636) (Issuer) https://www.quantisnow.com/insight/large-owner-chernett-jorey-sold-4479146-worth-of-shares-3335411-6791825 https://www.quantisnow.com/insight/large-owner-chernett-jorey-sold-4479146-worth-of-shares-3335411-6791825 Sat, 14 Nov 2026 02:43:51 GMT 4 - EXAGEN INC. (0001274737) (Issuer) https://www.quantisnow.com/insight/large-owner-chernett-jorey-sold-745795-worth-of-shares-167504-6791824 https://www.quantisnow.com/insight/large-owner-chernett-jorey-sold-745795-worth-of-shares-167504-6791824 Sat, 14 Nov 2026 02:43:33 GMT 4/A - Starling Oncology, Inc. (0001799191) (Issuer) https://www.quantisnow.com/insight/amendment-large-owner-chernett-jorey-acquired-1113-worth-of-call-6791823 https://www.quantisnow.com/insight/amendment-large-owner-chernett-jorey-acquired-1113-worth-of-call-6791823 Sat, 14 Nov 2026 02:43:08 GMT 4 - Reservoir Media, Inc. (0001824403) (Issuer) https://www.quantisnow.com/insight/large-owner-er-reservoir-llc-was-granted-488-shares-sec-6791822 https://www.quantisnow.com/insight/large-owner-er-reservoir-llc-was-granted-488-shares-sec-6791822 Sat, 14 Nov 2026 02:33:34 GMT SCHEDULE 13G/A - Evolent Health, Inc. (0001628908) (Subject) https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-evolent-health-inc-6791821 https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-evolent-health-inc-6791821 Sat, 14 Nov 2026 02:32:43 GMT 4 - Vivani Medical, Inc. (0001266806) (Issuer) https://www.quantisnow.com/insight/chief-business-officer-dwyer-donald-bought-19645-worth-of-shares-6791820 https://www.quantisnow.com/insight/chief-business-officer-dwyer-donald-bought-19645-worth-of-shares-6791820 Sat, 14 Nov 2026 02:32:17 GMT SCHEDULE 13D/A - Centuri Holdings, Inc. (0001981599) (Subject) https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-centuri-holdings-inc-6791819 https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-centuri-holdings-inc-6791819 Sat, 14 Nov 2026 02:30:46 GMT 4/A - Centuri Holdings, Inc. (0001981599) (Issuer) https://www.quantisnow.com/insight/amendment-large-owner-icahn-carl-c-sold-33711822-worth-of-6791818 https://www.quantisnow.com/insight/amendment-large-owner-icahn-carl-c-sold-33711822-worth-of-6791818 Sat, 14 Nov 2026 02:30:11 GMT 4 - Enovix Corp (0001828318) (Issuer) https://www.quantisnow.com/insight/chief-accounting-officer-truong-kristina-covered-exercisetax-liability-with-253-6791817 https://www.quantisnow.com/insight/chief-accounting-officer-truong-kristina-covered-exercisetax-liability-with-253-6791817 Sat, 14 Nov 2026 02:25:06 GMT 4 - Enovix Corp (0001828318) (Issuer) https://www.quantisnow.com/insight/chief-operating-officer-vyvoda-michael-was-granted-67600-shares-increasing-6791816 https://www.quantisnow.com/insight/chief-operating-officer-vyvoda-michael-was-granted-67600-shares-increasing-6791816 Sat, 14 Nov 2026 02:24:57 GMT 4 - Reservoir Media, Inc. (0001824403) (Issuer) https://www.quantisnow.com/insight/may-be-deemed-a-10-owner-taylor-ryan-p-was-6791815 https://www.quantisnow.com/insight/may-be-deemed-a-10-owner-taylor-ryan-p-was-6791815 Sat, 14 Nov 2026 02:24:53 GMT SCHEDULE 13G/A - Whitehawk Therapeutics, Inc. (0001422142) (Subject) https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-whitehawk-therapeutics-inc-6791814 https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-whitehawk-therapeutics-inc-6791814 Sat, 14 Nov 2026 02:24:42 GMT 4 - Enovix Corp (0001828318) (Issuer) https://www.quantisnow.com/insight/interim-ceo-benton-ryan-a-was-granted-550000-shares-increasing-6791813 https://www.quantisnow.com/insight/interim-ceo-benton-ryan-a-was-granted-550000-shares-increasing-6791813 Sat, 14 Nov 2026 02:24:44 GMT 4 - FAIR ISAAC CORP (0000814547) (Issuer) https://www.quantisnow.com/insight/president-and-ceo-lansing-william-j-sold-183750-worth-of-6791812 https://www.quantisnow.com/insight/president-and-ceo-lansing-william-j-sold-183750-worth-of-6791812 Sat, 14 Nov 2026 02:23:26 GMT SCHEDULE 13G/A - Minerva Neurosciences, Inc. (0001598646) (Subject) https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-minerva-neurosciences-inc-6791811 https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-minerva-neurosciences-inc-6791811 Sat, 14 Nov 2026 02:23:22 GMT SCHEDULE 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject) https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-xilio-therapeutics-inc-6791810 https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-xilio-therapeutics-inc-6791810 Sat, 14 Nov 2026 02:22:09 GMT 4 - FAIR ISAAC CORP (0000814547) (Issuer) https://www.quantisnow.com/insight/president-and-ceo-lansing-william-j-exercised-9782-shares-at-6791809 https://www.quantisnow.com/insight/president-and-ceo-lansing-william-j-exercised-9782-shares-at-6791809 Sat, 14 Nov 2026 02:21:46 GMT 4 - Reservoir Media, Inc. (0001824403) (Issuer) https://www.quantisnow.com/insight/director-koss-jennifer-g-was-granted-488-shares-increasing-direct-6791808 https://www.quantisnow.com/insight/director-koss-jennifer-g-was-granted-488-shares-increasing-direct-6791808 Sat, 14 Nov 2026 02:21:42 GMT 4 - STARWOOD PROPERTY TRUST, INC. (0001465128) (Issuer) https://www.quantisnow.com/insight/director-pollack-jonathan-lee-bought-2013450-worth-of-shares-169800-6791807 https://www.quantisnow.com/insight/director-pollack-jonathan-lee-bought-2013450-worth-of-shares-169800-6791807 Sat, 14 Nov 2026 02:21:30 GMT SCHEDULE 13G/A - Eloxx Pharmaceuticals, Inc. (0001035354) (Subject) https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-eloxx-pharmaceuticals-inc-6791806 https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-eloxx-pharmaceuticals-inc-6791806 Sat, 14 Nov 2026 02:20:52 GMT 4 - STARWOOD PROPERTY TRUST, INC. (0001465128) (Issuer) https://www.quantisnow.com/insight/ceo-chairman-of-the-board-sternlicht-barry-s-bought-14697682-6791805 https://www.quantisnow.com/insight/ceo-chairman-of-the-board-sternlicht-barry-s-bought-14697682-6791805 Sat, 14 Nov 2026 02:19:42 GMT 4 - Reservoir Media, Inc. (0001824403) (Issuer) https://www.quantisnow.com/insight/director-rothstein-adam-was-granted-488-shares-increasing-direct-ownership-6791804 https://www.quantisnow.com/insight/director-rothstein-adam-was-granted-488-shares-increasing-direct-ownership-6791804 Sat, 14 Nov 2026 02:19:40 GMT SCHEDULE 13G/A - X4 Pharmaceuticals, Inc (0001501697) (Subject) https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-x4-pharmaceuticals-inc-6791803 https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-x4-pharmaceuticals-inc-6791803 Sat, 14 Nov 2026 02:17:58 GMT 4 - Reservoir Media, Inc. (0001824403) (Issuer) https://www.quantisnow.com/insight/director-field-ezra-s-was-granted-1221-shares-increasing-direct-6791802 https://www.quantisnow.com/insight/director-field-ezra-s-was-granted-1221-shares-increasing-direct-6791802 Sat, 14 Nov 2026 02:16:44 GMT SCHEDULE 13G/A - Camp4 Therapeutics Corp (0001736730) (Subject) https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-camp4-therapeutics-corporation-6791801 https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-camp4-therapeutics-corporation-6791801 Sat, 14 Nov 2026 02:15:34 GMT SCHEDULE 13G/A - AN2 Therapeutics, Inc. (0001880438) (Subject) https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-an2-therapeutics-inc-6791800 https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-an2-therapeutics-inc-6791800 Sat, 14 Nov 2026 02:14:02 GMT 4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer) https://www.quantisnow.com/insight/director-reznick-yehuda-was-granted-75670-shares-increasing-direct-ownership-6791799 https://www.quantisnow.com/insight/director-reznick-yehuda-was-granted-75670-shares-increasing-direct-ownership-6791799 Sat, 14 Nov 2026 02:12:31 GMT 4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer) https://www.quantisnow.com/insight/director-shapiro-benjamin-was-granted-73830-shares-increasing-direct-ownership-6791798 https://www.quantisnow.com/insight/director-shapiro-benjamin-was-granted-73830-shares-increasing-direct-ownership-6791798 Sat, 14 Nov 2026 02:12:14 GMT 4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer) https://www.quantisnow.com/insight/director-mayer-arie-was-granted-74250-shares-increasing-direct-ownership-6791797 https://www.quantisnow.com/insight/director-mayer-arie-was-granted-74250-shares-increasing-direct-ownership-6791797 Sat, 14 Nov 2026 02:12:00 GMT 4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer) https://www.quantisnow.com/insight/director-aghion-daniel-was-granted-75670-shares-increasing-direct-ownership-6791796 https://www.quantisnow.com/insight/director-aghion-daniel-was-granted-75670-shares-increasing-direct-ownership-6791796 Sat, 14 Nov 2026 02:11:47 GMT 4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer) https://www.quantisnow.com/insight/president-and-ceo-kidron-nadav-was-granted-1317000-shares-increasing-6791795 https://www.quantisnow.com/insight/president-and-ceo-kidron-nadav-was-granted-1317000-shares-increasing-6791795 Sat, 14 Nov 2026 02:11:35 GMT 4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer) https://www.quantisnow.com/insight/coo-cbo-hexter-joshua-was-granted-599000-shares-increasing-direct-6791794 https://www.quantisnow.com/insight/coo-cbo-hexter-joshua-was-granted-599000-shares-increasing-direct-6791794 Sat, 14 Nov 2026 02:11:23 GMT